Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

The Effect of 'Mindfulness of Breathing' on Chronic Migraine

13 novembre 2026 aggiornato da: Dr Ashish Kumar Duggal, Dr. Ram Manohar Lohia Hospital

Migraine is a common disabling primary headache disorder ranked as the third most prevalent disorder in the world. Chronic migraine (CM) is described as a headache occurring on 15 or more days/month for more than 3 months, which, on at least 8 days/month, has the features of a migraine headache. Chronic migraine typically evolves from episodic migraine with an annual progression rate of ~3%. CM is an important treatable cause of neurological disability . It impacts, on an average, 1.4-2.2% of the global population and imposes a significant individual and socioeconomic burden with disability scores reported to be nearly twice as high.

It is vital to make a diagnosis and ensure that any concomitant medical or psychological conditions are treated in parallel with interventions aimed at reducing the biological tendency to headaches. The conventional treatment for migraine therapy is medical therapy. However only half of the patients respond to medications and preventive drug treatments; and about 10% discontinue medications due to adverse events. Moreover almost half of the patients are not satisfied with the present treatment. There is a clear need for additional preventive strategies in the current treatment regimens for migraines due to existing shortcomings of medical management of CM. In addition, there are other tactics that can be used, such as practicing alternative medicine through Yoga and Meditation.

Meditation has been found to help in reducing stress and changing the psychological state of a person. Mindfulness meditation has been derived from Vipassana, an age old meditation technique and has been practiced since long. Buddhist literature has detailed description about the techniques of Vipassana. Mindfulness of Breathing called as 'Anapanasati Meditation', in Buddhist scriptures is the first step in the practice of Vipassana meditation. It is a technique that involves observing natural and normal breathing. As it enters and exits the body our breath acts as a connection between our conscious and unconscious minds and the voluntary and involuntary processes of our body. By observing our breath, we can gain insight into the nature of our mind and its tendency to be inconsistent and fleeting.Slowly, this technique helps develop concentration of the mind and become calm. . It is a simple and scientific method that can be easily learned. Using Mindfulness of Breathing (Anapanasati) as a tool to reduce stress can be helpful in reducing the disability associated with migraines, as stress is a common trigger for migraines.

In the present study we aim to evaluate the beneficial effects of this simple meditation technique in management of CM.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

80

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 60 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:-1. All patients between 18-60 years of age fulfilling the criteria for chronic migraine as defined by ICHD -3.3 2. Patients willing to carry out meditation as prescribed. 3. Patients on a maximum of one concomitant preventive medication for not less than 3 months duration and a stable dose for at least 1 month prior to randomization.

Exclusion Criteria:-1. 1.Patients < 18 years and > 60 years of age. 2. Prior Neurologic diseases like brain tumors, dementia, seizures, encephalitis, meningitis, and stroke. 3. Patients overusing barbiturate-containing analgesics, opioids, or subjects with medical conditions attributable to medication overuse (e.g. peptic ulcer disease from overuse of nonsteroidal anti-inflammatory drugs [NSAIDS]).

4. Patients who did not complete the headache diary for more than 6 non-consecutive days during the baseline period.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Ricerca sui servizi sanitari
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Supervised Meditation Group

The 'Meditation' group will take part in structured 'Mindfulness of Breathing' meditation sessions. A total of five sessions will be conducted on days 0, 7, 14, 28 and week 8th at the Yoga Department of ABVIMS and Dr RML Hospital. These sessions will be supervised by a yoga instructor who will explain the procedure and answer any queries. The patients will then practice the meditation alongside the instructor, as described in the subsequent sections. They will also be encouraged to continue this practice daily at home, using a 20-minute audio guide featuring the voice of the 'Late Shri S.N. Goenka Ji'. Additionally, the 'Meditation group' will join a WhatsApp group for enhanced supervision by the Yoga instructor, in which members will be required to provide daily updates after their meditation sessions. If they fail to report their daily meditation, the admin would remind them to ensure that they complete it, and their queries and issues will also addressed.

The technique taught by the late Shri S.N. Goenka Ji involved sitting with closed eyes in a quiet room with minimal distractions, maintaining a comfortable posture with the spine straight and hands resting on the thighs, without requiring any specific mudra for 20 minutes daily.The practitioner will have to observe the breath as instructed, without judging its length or type. The nature of the breath will have to be accepted as it is and should not be altered. Any thoughts that arise are to be acknowledged without judgment. If the mind wanders, one has to notice this and gently shift awareness back to the breath without clinging to it or wishing it to be different. If any pain, discomfort, or other sensations are felt, these are to be acknowledged with awareness before returning attention to the breath. The subject simply follows the instructions of a pre-recorded 'Mindfulness of Breathing Meditation (Anapana)' audio provided by the yoga instructor throughout the sessions.

Comparatore fittizio: Unsupervised Meditation Group

The Unsupervised meditation/Sham group will practice meditation on their visits-on days 0, 7, 14, 28, and week 8-without any supervision. The Yoga instructor will merely guide them once to independently concentrate on their breathing. They will not be provided any audio. This will serve as a sham group for more effective comparison and ensured blinding.

Patients were told to meditate on their own .They were not provided with any structured meditation technique. They were told to meditate in a quiet room with minimal distractions, maintaining a comfortable posture with the spine straight and hands resting on the thighs, without requiring any specific mudra for 20 minutes daily on their own without any specific instructions.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To assess the change in headache days at 12 weeks from baseline.
Lasso di tempo: From enrollment to 12 Weeks.

Change in frequency of moderate-severe headache days per month from baseline (Headache-day is defined as a calendar day [00:00 to 23:59] when the patient reported > 4 continuous hours of headache in the diary) during the month 2-3.

From enrollment to 12 Weeks.

Misure di risultato secondarie

Misura del risultato
Lasso di tempo
Change in migraine days (week 8 - 12 vs baseline)
Lasso di tempo: 12 weeks
12 weeks
50% responder rate
Lasso di tempo: 12 weeks
12 weeks

Altre misure di risultato

Misura del risultato
Lasso di tempo
Change in headache severity (week 8 - 12 vs baseline)
Lasso di tempo: 12 weeks
12 weeks
Change in number of days with acute medication use (week 8 - 12 vs baseline)
Lasso di tempo: 12 weeks
12 weeks
Change in PHQ-9 scores (week 8 - 12 vs baseline)
Lasso di tempo: 12 weeks
12 weeks
Change in MIDAS score ( week 8-12 vs baseline)
Lasso di tempo: 12 weeks
12 weeks
Change in HIT (week 8-12 vs baseline)
Lasso di tempo: 12 weeks
12 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 novembre 2026

Completamento primario (Stimato)

15 agosto 2027

Completamento dello studio (Stimato)

15 agosto 2027

Date di iscrizione allo studio

Primo inviato

13 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 novembre 2026

Primo Inserito (Effettivo)

19 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • IEC/ABVIMS/RMLH/1410

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

IPD related to the study will be shared by the principal investigator on request.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi